Latest News-CALIWAY BIOPHARMACEUTICALS Mediaroom_Page

Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum's Disease Treatment

- CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease tr...

2024-11-13 13:36 1120

Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum's Disease Treatment

Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction

* The first and only lipolytic injectable for large area – CBL-514's last Phase2b study has been ...

2024-10-24 01:42 1516

Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease

NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that ...

2024-09-03 15:18 1189

Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention

NEW TAIPEI CITY, May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to an...

2024-05-11 15:14 3297

Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints

* CBL-514 is the first product to treat cellulite at the raised areas. * Currently, there is no ...

2024-04-26 01:25 1409

Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease

* CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track desig...

2024-03-04 16:22 1609

Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease

- CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track d...

2024-03-04 07:00 1961

Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that ...

2024-01-23 21:12 1694

Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that ...

2024-01-23 18:35 1308

Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum's Disease

NEW TAIPEI CITY, Jan. 8, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that t...

2024-01-08 13:25 2130

Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction at IMCAS 2024

CBL-514 Phase 2 Study Results for local fat reduction demonstrated 85.7% and 76.2% of participants...

2023-12-27 11:49 1772

Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction

TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has cl...

2023-12-16 15:47 2035

Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study

- CBL-0202 Phase 2 study results met all the primary and secondary endpoints. - 69.9% and 60.9% of p...

2023-10-02 21:00 1265

Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment

TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway), a biopharmaceutical co...

2023-09-19 11:16 1254

Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7

- CBL-0201DD Phase 2 study met the primary and all secondary endpoints. - 64.5% of pain...

2023-09-13 13:42 1373

Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite

* CBL-514 is the only non-invasive product that can improve 1-level of cellulite severity two wee...

2023-06-28 18:30 1863

Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction

- Caliway has initiated the subject recruitment in CBL-0204 Phase 2b study. - The study is expected...

2023-05-31 20:15 3190